BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 9, 2026
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Biggest gainers and losers for April 17-21, 2023

April 24, 2023
The top 10 biopharma stock gainers and losers for the week.
Read More
International currency symbols

Med-tech financings are low, slow, and down in Q1

April 21, 2023
By Karen Carey
The amount of money raised by med-tech companies in the first quarter (Q1) of 2023 is the lowest amount raised for the industry during any quarter going back to 2018.
Read More

Biopharma money raised: Jan. 1-April 20, 2023

April 21, 2023
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma

April 21, 2023
Total raised in public, private and other financings of biopharma companies, comparing 2023 vs. 2022 vs. 2021 vs. 2020 vs. 2019.
Read More
Hands holding puzzle pieces with digital globe overlay

Biopharma deals slip in Q1, completed M&As remain low

April 18, 2023
By Karen Carey
Despite strong deal activity throughout each of the last two years, the volume and value of partnerships began sliding in the first quarter (Q1) of 2023, while M&As continue to trail several other years.
Read More

Med-tech gainers and losers for April 10-14, 2023

April 17, 2023
The top 10 med-tech stock gainers and losers for the week.
Read More

Biggest gainers and losers for April 10-14, 2023

April 17, 2023
The top 10 biopharma stock gainers and losers for the week.
Read More

Surging demand for orthopedic trauma devices driving innovation

April 14, 2023
By Naum O’Brien
The growing number of people taking up more active sports in China is powering the global market for orthopedic trauma devices through a surge in demand and the emergence of new lines of surgical products, particularly ones that can improve patient outcomes and experience.
Read More

Biopharma money raised: Jan. 1-April 13, 2023

April 14, 2023
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma

April 14, 2023
Total raised in public, private and other financings of biopharma companies, comparing 2023 vs. 2022 vs. 2021 vs. 2020 vs. 2019.
Read More
Previous 1 2 … 154 155 156 157 158 159 160 161 162 … 316 317 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 8, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • China compass

    ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

    BioWorld
    If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • Woman taking medication for mental illness

    Autobahn on the fast track with bipolar thyroid agonist

    BioWorld
    Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing